SPONSOR
LaNova Medicines Limited
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 1, Phase 2
LaNova Medicines Limited is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Malignant Tumors.
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — LaNova Medicines Limited
How many clinical trials has LaNova Medicines Limited sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by LaNova Medicines Limited, of which 2 are actively recruiting participants. These trials cover conditions including Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Malignant Tumors. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does LaNova Medicines Limited research focus on?
LaNova Medicines Limited clinical trials span Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, Malignant Tumors. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a LaNova Medicines Limited clinical trial?
To participate in a LaNova Medicines Limited trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all LaNova Medicines Limited trials with current recruitment status updated daily.
Clinical Trials by LaNova Medicines Limited
NCT07362186 Phase 3
Recruiting
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
NCT06650566 Phase 1, Phase 2
Recruiting
Study of LM-299 in Subjects Advanced Malignant Tumors
Malignant Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology